

Clinical and Translational Oncology

Prognostic factors in neoadjuvant treatment followed surgery in stage IIIA-N2 non-small-cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

--Manuscript Draft--

Manuscript Number:	CLAT-D-18-00289R1
Full Title:	Prognostic factors in neoadjuvant treatment followed surgery in stage IIIA-N2 non-small-cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Article Type:	Research Article
Keywords:	non-small cell lung cancer; N2 disease; neoadjuvant therapy; Surgery; Survival.
Corresponding Author:	Felipe Couñago, Ph.D Hospital Universitario Quirónsalud Madrid Madrid, Madrid SPAIN
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Hospital Universitario Quirónsalud Madrid
Corresponding Author's Secondary Institution:	
First Author:	Felipe Couñago, M.D; PhD
First Author Secondary Information:	
Order of Authors:	Felipe Couñago, M.D; PhD
	Sara Montemuiño, MD
	Margarita Martin, MD;PhD
	Begoña Taboada, MD
	Patricia Calvo-Crespo, MD
	Maria Pilar Samper-Ots, Md;PhD
	Pino Alcántara, MD;PhD
	Juan Corona, MD
	Jose Luis López-Guerra, MD;PhD
	Mauricio Murcia, MD
	Miriam López-Mata, MD
	Josep Jové-Teixidó, MD
	Marisa Chust, MD
	Verónica Díaz-Díaz, MD
	Lourdes de Ingunza-Barón, MD
	Tamara García-Cañibano, MD
	María Luz Couselo, MD
	Elia del Cerro, MD
	Javier Moradiellos, MD
	Sergio Amor, MD
	Andrés Varela

	María Mar Puertas, MD
	Israel J Thuissard, B.Ec
	David Sanz-Rosa, PhD
	Nurias Rodríguez de Dios, MD;PhD
Order of Authors Secondary Information:	
Funding Information:	The translation of this work was supported financially by the Spanish Society of Radiation Oncology. Dr. Felipe Couñago
Abstract:	<p>PPurpose: To evaluate the prognostic factors associated with survival in patients treated with neoadjuvant treatment (chemoradiotherapy [CRT] or chemotherapy) followed by surgery (CRTS) in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC).</p> <p>Methods: Retrospective study of 118 patients diagnosed with stage T1-T3N2M0 NSCLC and treated with CRTS at 14 hospitals in Spain between January 2005 and December 2014. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was performed.</p> <p>Results: Surgery consisted of lobectomy (74.5% of cases), pneumectomy (17.8%), or bilobectomy (7.6%). Neoadjuvant treatment was CRT in 62 patients (52.5%) and chemotherapy alone in 56 patients (47.5%). Median follow-up was 42.5 months (5-128 months). Five-year OS and PFS were 51.1% and 49.4%, respectively. The following variables were independently associated with worse OS and PFS: pneumonectomy (vs. lobectomy); advanced pathologic T stage (pT3 vs. pT0-pT2), and presence of persistent N2 disease (vs. ypN0-1) in the surgical specimen.</p> <p>Conclusions: In this sample of patients with stage IIIA-N2 NSCLC treated with CRTS, 5-year survival (both OS and PFS) was approximately 50%. After CRTS, the patients with the best prognosis were those whose primary tumour and/or mediastinal nodal metastases were downstaged after induction therapy and those who underwent lobectomy. These findings provide further support for neoadjuvant therapy followed by surgery in selected patients.</p>
Response to Reviewers:	<p>Dr. Pere Gascon Editor-in-Chief Clinical and Translational Oncology</p> <p>Dear Dr. Pere Gascon</p> <p>We appreciate the thorough revision done by reviewers. Below we are answering point by point all comments/questions/suggestions and the manuscript has been changed accordingly. We thank the reviewers for constructive and thorough criticisms, which have helped us to considerably strengthen the manuscript.</p> <p>Reviewer #2: Thanks to the Clinical and Translational Oncology magazine's editor for giving me an opportunity to review this paper, Induction Treatment and Surgery for Stage IIIA-N2 Non-small-cell Lung Cancer: A Multi-institutional Study by The Oncologic Group for The Study of Lung Cancer. In this article, researchers collected retrospectively 118 patients who were diagnosed as stage T1-T3N2M0 NSCLC and treated with neoadjuvant treatment (chemoradiotherapy [CRT] or chemotherapy) followed by surgery at 14 hospitals in Spain between January 2005 and December 2014. In the end of study, researchers got some interesting outcomes. In this sample of patients with stage IIIA-N2 NSCLC treated with CRTS, 5-year survival (both OS and PFS) was approximately 50%. After CRTS, the patients with the best prognosis were those whose primary tumor and/or mediastinal nodal metastases were downstaged after induction therapy and those who underwent lobectomy. There are some comments about this study.</p> <p>1) At the first of all, the purpose of this article is not clear, the five-year overall survival</p>

and five-year progress-free survival in patients undergoing preoperative CRT and preoperative chemotherapy alone are blurred.
As the reviewer suggests, we have clarified the objective of the study in the abstract, main text and the title. The objective of the study was: "To evaluate the prognostic factors associated with survival in patients treated with neoadjuvant treatment (chemoradiotherapy [CRT] or chemotherapy) followed by surgery (CRTS) in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC)". For this reason, we have changed the title of the manuscript.
The type of neoadjuvant treatment (CRT vs. chemotherapy) was not an independent prognostic factor associated with OS in the univariate study (table 3) and, therefore, it was not included in the multivariate analysis.

2) The second, this study did not explain what type of patient received postoperative adjuvant chemotherapy or postoperative adjuvant radiotherapy and include postoperative adjuvant therapy in univariate or multivariate analysis. Moreover, the study couldn't rule out interference of postoperative adjuvant chemotherapy, which belonged to the retrospective study.
As the reviewer suggests, we have clarified the type of adjuvant treatment administered to patients in our cohort. This data has been included in the univariate analysis (table 3), and it was not statistically significant, therefore it was not included in the multivariate analysis.

3) The next, the study did not include the comparison of the side effects of neoadjuvant chemoradiation and neoadjuvant chemotherapy, and the comparison of perioperative complications.
According to the reviewer comment, toxicity and mortality have been specified in the main text according to the type of neoadjuvant treatment performed.

4) The study did not include the comparison of the rate of downstaged between neoadjuvant chemoradiation and neoadjuvant chemotherapy, and the comparison of rate of pathologic complete response between neoadjuvant chemoradiation and neoadjuvant chemotherapy. These data is very interesting to the reader.
As the reviewer suggests, downstaging and pathologic complete response rates between neoadjuvant chemoradiation and neoadjuvant chemotherapy was added in the main text.

5) And then, In Figure 1 C and Figure 2 C , Neumonectomy should be Pneumonectomy.
The error has been corrected.

6) In the end, were there any relations of data between this article and another article, Neoadjuvant Treatment Followed by Surgery Versus Definitive Chemoradiation in Stage IIIA-N2 Non-small-cell Lung cancer: A Multi-institutional Study by The Oncologic Group for The Study of Lung Cancer?
What were the differences between the two articles?

Both studies answer different questions. The first article tries to answer whether surgical treatment increases survival in patients IIIA-N2 NSCLC compared with exclusive chemoradiotherapy. However, the present manuscript analyzes the prognostic factors associated with survival in a subgroup of patients treated with surgery. The information provided by each of the studies is different. The present manuscript includes new information that has not been included in the previous one.

Reviewer #3: Quite good job! A large retrospective study of multiple centers, but the heterogeneity of the sample should be evaluated, for example, is different surgery team the independent survival predictor?

As third reviewer suggests, survival analysis was performed based on number of patients included per hospital, and we have found no differences. See Table:
cases recruited by surgical team for this study Median survival (months)
> 10 patients 42

	< 10 patients	43
Additional Information:		
Question	Response	
Article text word count:	2986	
Structured Abstract word count:	222	
No. of figures:	2	
No. of tables:	4	
No. of references:	18	
No. of keywords:	5	

TITLE PAGE

Title: "Prognostic factors in neoadjuvant treatment followed surgery in stage IIIA-N2 non-small-cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)".

Authors: Felipe Couñago, MD, PhD^{1,2}; Sara Montemuiño, MD³; Margarita Martin, MD, PhD⁴; Begoña Taboada, MD⁵; Patricia Calvo-Crespo, MD⁵; María Pilar Samper-Ots, MD, PhD⁶; Pino Alcántara, MD, PhD⁷; Juan Corona, MD⁷; José Luis López-Guerra, MD, PhD⁸; Mauricio Murcia-Mejía, MD⁹; Miriam López-Mata, MD¹⁰; Josep Jové-Teixidó, MD¹¹; Marisa Chust, MD¹²; Verónica Díaz-Díaz, MD¹³; Lourdes de Ingunza-Barón, MD¹³; Tamara García-Cañibano, MD³; María Luz Couselo, MD¹⁴; Elia del Cerro, MD^{1,2}; Javier Moradiellos, MD¹⁵; Sergio Amor, MD¹⁵; Andrés Varela, MD, PhD¹⁵; María Mar Puertas, MD¹⁶; Israel J. Thuissard, B.Ec¹⁷; David Sanz-Rosa, B.Sc, PhD¹⁷; and Núria Rodríguez de Dios, MD, PhD^{18,19}.

¹*Department of Radiation Oncology. Hospital Universitario Quirónsalud Madrid. C/ Diego de Velázquez, 1, 28223, Pozuelo de Alarcón. Madrid. Spain.*

²*Universidad Europea de Madrid. Calle Tajo, s/n, 28670 Villaviciosa de Odón, Madrid. Spain.*

³*Department of Radiation Oncology. Hospital Universitario de Fuenlabrada, Camino del Molino, 2, 28942, Fuenlabrada, Madrid.*

⁴*Department of Radiation Oncology. Hospital Universitario Ramon y Cajal, Carretera de Colmenar Viejo Km9, Madrid, Spain.*

⁵*Department of Radiation Oncology. Complejo Hospitalario Universitario Santiago de Compostela, Choupana s/n, bloque d. Santiago de Compostela, A Coruña, Spain.*

⁶*Department of Radiation Oncology. Hospital Universitario Rey Juan Carlos, C/ Gladiolo s/n. Móstoles, Madrid, Spain.*

⁷*Department of Radiation Oncology. Hospital Universitario Clínico San Carlos, C/Prof. Martín Lagos s/n, Madrid, Spain.*

⁸*Department of Radiation Oncology, Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, S/N, 41013 Sevilla, Spain.*

⁹*Department of Radiation Oncology. Hospital Universitari Sant Joan de Reus, Av. del Dr. Josep Laporte, 2, 43204 Reus, Tarragona, Spain.*

¹⁰*Department of Radiation Oncology. Hospital Clinico Universitario Lozano Blesa, San Juan Bosco 15, Zaragoza, Spain.*

¹¹*Department of Radiation Oncology. Hospital Germans Trias i Pujol. Carretera de Canyet, s/n, 08916, Badalona, Spain.*

1 ¹²Department of Radiation Oncology. Instituto Valenciano de Oncología, Carrer del Professor
2 Beltrán Báguena, 8, 46009, Valencia, Spain.1

3 ¹³Department of Radiation Oncology. Hospital Universitario Puerta del Mar, Av. Ana de Viya,
4 21, 11009, Cadiz, Spain..

5
6 ¹⁴Department of Radiation Oncology. Hospital Central de la Defensa Gomez Ulla, Glorieta
7 Ejército, 1, 28047, Madrid, Spain

8
9
10 ¹⁵Department of Thoracic Surgery. Hospital Universitario Quirónsalud Madrid. C/ Diego de
11 Velázquez, 1, 28223, Pozuelo de Alarcón. Madrid. Spain.

12
13 ¹⁶Department of Radiation Oncology. Hospital Universitario Miguel Servet, Paseo Isabel la
14 Católica, 1-3, 50009, Zaragoza, Spain.

15
16
17 ¹⁷School of Doctoral Studies & Research, Universidad Europea, Calle Tajo, s/n, 28670
18 Villaviciosa de Odón, Madrid, Spain. I1

19
20 ¹⁸Department of Radiation Oncology. Hospital del Mar. Passeig Marítim, 25-29, 08003
21 Barcelona, Spain.

22
23
24 ¹⁹IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

25
26
27 **Corresponding Author:**

28
29
30 Felipe Couñago Lorenzo

31
32
33 Department of Radiation Oncology,

34
35
36 Hospital Universitario Quirónsalud Madrid,

37
38
39 Calle Diego de Velázquez, 1, 28223,

40
41
42 Pozuelo de Alarcón, Madrid, Spain

43
44
45 e-mail: felipe.counago@quironsalud.es

46
47
48 Phone: +34 676839746; Fax: +34 915183232

Abstract

Purpose: To evaluate the prognostic factors associated with survival in patients treated with neoadjuvant treatment (chemoradiotherapy [CRT] or chemotherapy) followed by surgery (CRTS) in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC).

Methods: Retrospective study of 118 patients diagnosed with stage T1-T3N2M0 NSCLC and treated with CRTS at 14 hospitals in Spain between January 2005 and December 2014. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was performed.

Results: Surgery consisted of lobectomy (74.5% of cases), pneumectomy (17.8%), or bilobectomy (7.6%). Neoadjuvant treatment was CRT in 62 patients (52.5%) and chemotherapy alone in 56 patients (47.5%). Median follow-up was 42.5 months (5-128 months). Five-year OS and PFS were 51.1% and 49.4%, respectively. The following variables were independently associated with worse OS and PFS: pneumonectomy (vs. lobectomy); advanced pathologic T stage (pT3 vs. pT0-pT2), and presence of persistent N2 disease (vs. ypN0-1) in the surgical specimen.

Conclusions: In this sample of patients with stage IIIA-N2 NSCLC treated with CRTS, 5-year survival (both OS and PFS) was approximately 50%. After CRTS, the patients with the best prognosis were those whose primary tumour and/or mediastinal nodal metastases were downstaged after induction therapy and those who underwent lobectomy. These findings provide further support for neoadjuvant therapy followed by surgery in selected patients.

Keywords: Non-small cell lung cancer; N2 disease; neoadjuvant therapy; surgery; survival.

Introduction

Patients diagnosed with stage IIIA-N2 non-small cell lung carcinoma (NSCLC) comprise a heterogeneous group. Treatment outcomes in patients treated with surgery or radiotherapy alone are poor, with 5-year overall survival (OS) rates of < 10% [1]. The current standard of care, based on the findings from two meta-analyses [2,3], is concomitant chemoradiotherapy (CRT), which achieves better but still relatively modest survival outcomes (5-year OS of approximately 20%) [2,3]. Given these poor outcomes, numerous phase II and III trials have evaluated neoadjuvant treatment followed by surgery in patients with potentially-resectable N2 disease [4-7]. Although no randomized study has demonstrated a survival advantage for this approach versus CRT alone, the results of these trials suggest that a subgroup of patients could benefit—in terms of local control and survival—from the addition of surgery [4,8,9].

Compared to neoadjuvant chemotherapy alone, CRT improves downstaging of primary tumour and lymph nodes, and also increases complete pathological response rates. However, surprisingly, these improvements have not resulted in better OS [8,10]. In this context, the aim of this retrospective Spanish multicenter study was to evaluate the prognostic factors associated with survival in patients treated with neoadjuvant treatment (chemoradiotherapy [CRT] or chemotherapy) followed by surgery (CRTS) in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC).

Materials and methods

Study population

This retrospective study was based on clinical records from 14 hospitals in Spain. The study was approved by the ethics committees of all participating hospitals. The study was supported by the Radiation Oncology Clinical Research Group (GICOR) and the GOECP-SEOR (Oncologic Group for the Study of Lung Cancer-Spanish Society of Radiation Oncology).

1 The study sample included patients diagnosed between the years 2005 and 2014 with
2 potentially-resectable stage IIIA-N2 NSCLC (T1-3 N2 M0) and treated with radical intent
3 induction therapy followed by surgery. Exclusion criteria were: stage cT4 disease and definitive
4 chemoradiotherapy (dCRT). Inclusion criteria were: mediastinal lymph node involvement on
5 imaging studies. Whenever possible, the mediastinal disease was confirmed histologically by
6 endobronchial ultrasound (EBUS), endoscopic ultrasound (EUS), or mediastinoscopy and
7 treated with chemotherapy or CRT followed by surgery. Clinical staging was based on thoracic
8 computed tomography (CT), positron-emission tomography-CT (PET-CT), and brain CT or
9 magnetic resonance imaging (MRI) and classified according to the TNM staging system (7th
10 edition).

21 **Treatment scheme and follow-up**

22
23
24
25
26
27 Neoadjuvant treatment consisted of 3-4 cycles of chemotherapy alone (platinum-based doublets)
28 or concomitant CRT. The radiotherapy dose ranged from 45-66 Gy and was delivered with a
29 conventional fractionation scheme (1.8-2 Gy/fraction) to the tumour volume. No elective nodal
30 irradiation was performed. The radiotherapy technique was three-dimensional radiotherapy (3D-
31 RT).

32
33
34
35
36
37
38
39 Response to neoadjuvant treatment was evaluated using the Response Evaluation Criteria in
40 Solid Tumours (RECIST) based on either CT or PET-CT. In some cases—depending on the
41 specific protocol at the participating hospital—the mediastinal nodes were reassessed
42 histologically by EUS, EBUS or mediastinoscopy after induction therapy. The time elapsed
43 from finalisation of neoadjuvant treatment until surgery was recorded in days. Surgical
44 treatment consisted of lobectomy or pneumonectomy, with homolateral hilar and mediastinal
45 lymphadenectomy.

46
47
48
49
50
51
52
53
54
55
56 Pathologic complete response (pCR) was defined as the absence of viable tumour in the resected
57 specimen. **Delivered adjuvant treatment depending on the specific protocol of each centre.**

1 Follow-up was performed weekly during neoadjuvant treatment, postoperatively every 3-6
2 months for the first two years, every 6 months for the next three years, and annually thereafter.
3
4 Acute and chronic hematological, gastrointestinal, thoracic and pulmonary toxicity were
5 recorded according to the Common Toxicity Criteria for Adverse Events (v. 4.0).
6
7

8
9
10 The date of recurrence was defined as the day an abnormal imaging test result was detected
11 during follow-up. Locoregional relapse was defined as a recurrence to the ipsilateral lung and/or
12 nodal regions (hilum, mediastinum, supraclavicular fossa). Distant relapse was defined as a
13 recurrence in other locations according to the staging criteria of the American Joint Committee
14 on Cancer (AJCC).
15
16
17
18
19

20 21 22 **Statistical analysis**

23
24
25 OS was defined as the time elapsed from the date of pathological diagnosis until the date of
26 death or last follow-up. PFS was calculated from the date of the pathological diagnosis until
27 first recurrence, death from any cause, or last final follow-up. OS and PFS were estimated using
28 the Kaplan-Meier method. The log-rank test was used to compare survival curves between
29 groups. Multivariate analysis was performed using the Cox proportional hazards model to
30 determine the variables significantly associated with survival. Statistical significance was set at
31 $p < 0.05$. Statistical analyses were performed using SPSS statistical software, version 22.0 (SPSS
32 Statistics for Windows, IBM Corporation, Armonk, NY).
33
34
35
36
37
38
39
40
41
42
43
44

45 **Results**

46 47 48 **Patient characteristics**

49
50
51 The initial database search identified 294 patients diagnosed with stage IIIA-N2 NSCLC. Of
52 these, 176 patients had received dCRT and were excluded from the study. A total of 118
53 patients were included. Patient characteristics are described in Table 1. In 69 cases (58.5%),
54 mediastinal involvement was confirmed histologically at diagnosis. Median age was 62 years
55
56
57
58
59

1 (range 41-78) and 94 patients (79.7%) were men. The Eastern Cooperative Oncology Group
2 (ECOG) score was 0 or 1 in nearly all cases (99.2%). In most cases (72 patients; 61%), only a
3 single mediastinal lymph node station was involved at diagnosis. The clinical T stage was as
4 follows: cT1 in 30 patients (25.5%), cT2 in 41 patients (35%), and cT3 in 46 patients (39.3%).
5
6 Histologically, adenocarcinoma accounted for just over half of the cases (50.4%).
7
8
9

10 11 **Neoadjuvant and postoperative treatment**

12
13
14
15 Neoadjuvant treatment consisted of CRT in 66 patients (56%) and chemotherapy alone in 52
16 patients (44%). Neoadjuvant radiotherapy doses were over 50 Gy in 47 patients (71.2%). The
17 most common fractionation schedule (69.7%) was 2 Gy/session. Radiotherapy was delivered
18 using the 3D technique in 97% of patients who underwent radiotherapy. In most cases (93.2%),
19 the chemotherapy regimen consisted of three cycles with a platinum-based doublet.

20
21
22
23
24
25
26
27 **Postoperatively 51 patients received adjuvant treatment: 20 (39.2%) received only adjuvant**
28 **chemotherapy, 20 (39.2%) underwent only radiotherapy (45-50 Gy) and 11 (21.6%) received**
29 **both treatments.**
30

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

95 96 **Surgery**

97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

(39.8%), with negative findings in most cases (89.3%). The median time interval from completion of neoadjuvant therapy until surgery was 60 days (Table 2).

The most frequent surgical procedure was lobectomy (74.6%), followed by pneumectomy (17.8%) and bilobectomy (7.6%). Two deaths (4%), both treated with neoadjuvant CRT, due to acute respiratory distress syndrome occurred within 90 days of surgery; of these, one patient had undergone lobectomy and the other pneumectomy.

Pathologic findings

A complete resection (R0) was achieved in most cases (95,8%) while 3 patients (2.6%) presented microscopic involvement (R1) of the margins and 1 patient (0.9%) had macroscopic involvement (R2). The pathological T stage in the sample was distributed as follows: ypT0 in 34 patients (28.8%), ypT1 in 49 (41.5%), ypT2 in 22 (18.6%), and ypT3 in 13 (11%). The pathological N stage was ypN0 in 81 patients (68.6%), ypN1 in 7 (5.9%), and ypN2 in 30 (25.4%). pCR in the primary tumour and mediastinal nodes (pT0pN0) was obtained in 32 patients (27.1%), 6 (18.7%) treated with CHT chemotherapy neoadjuvant vs. 26 (81.2%) treated with CRT neoadjuvant ($p<0.001$). A downstaging from N2 to ypN1-N0 was observed in 88 patients (74.6%), 33 (37.5%) treated with CHT chemotherapy neoadjuvant vs. 55 (62.5%) treated with CRT neoadjuvant ($p<0.001$).

Overall survival

The median follow-up time was 42.5 months, with a mortality rate of 43.2% (51 patients). Median OS was 61 months (95% confidence interval [CI], 39.9 – 82.1). Five-year OS was 51.1% (95% CI, 40.1 - 62.0). By pathological T stage, 5-year OS rates were: ypT0 (65.3%), ypT1 (55%), ypT2 (40.4%), and ypT3 (23.1%) ($p<0.001$, Fig. 1). Patients who experienced nodal downstaging presented a significantly better 5-year OS than patients with persistent N2 disease (59.2% vs. 28.5%; $p<0.001$, Fig. 1). The median OS in the lobectomy group was

1 significantly higher than in the pneumonectomy group (82 vs. 35 months; $p=0.012$), with a
2 significant difference in 5-year OS (54.3% vs. 36.6%; $p=0.06$). Five-year OS rates were
3 significantly better in patients who achieved pCR versus those with persistent tumour disease
4 (65.4% vs. 46.3%, $p=0.03$), although differences in median OS were not significant (82 vs. 56
5 months, $p=0.12$) (Fig. 1).
6
7
8
9

10
11 Based on the univariate and the Cox multivariate analyses, the following variables were
12 independently associated with worse OS: advanced pathologic T stage (pT3 vs. pT0-pT1),
13 pneumonectomy (vs. lobectomy), and persistent N2 (vs. ypN0-1). **The type of neoadjuvant**
14 **treatment (CRT vs. chemotherapy) was not a prognostic factor associated with OS.** (Table 3).
15
16
17
18
19
20
21

22 **Progression-free survival**

23
24
25 During follow up, 55 patients (46.6%) experienced a recurrence. The median time to first
26 recurrence was 32 months. Locoregional recurrence occurred in 29 patients (24.6%), distant in
27 39 (33.1%), and both in 13 patients (11%).
28
29
30
31

32
33 The median PFS was 58 months (95% CI, 22.6 – 93.4) with a 5-year PFS of 49.4% (95% CI,
34 39.0 - 59.7). By pathological T stage, 5-year PFS rates were: ypT0 (65.4%), ypT1 (55.1%),
35 ypT2 (32.7%), and ypT3 (15.4%) ($p<0.001$, Fig. 2). PFS was better in patients who achieved
36 nodal downstaging compared with persistent N2 (60.3% vs. 18.4%, $p<0.001$). Median PFS was
37 significantly longer in patients who underwent lobectomy versus pneumonectomy (61 vs. 32
38 months, $p=0.008$), with a non-significant difference in 5-year PFS in the lobectomy group
39 (51.8% vs. 38.6%, $p=0.08$). Patients who achieved pCR presented a better 5-year PFS than
40 those with persistent disease (68.7% vs. 42.4%), but this difference did not reach statistical
41 significance ($p=0.05$).
42
43
44
45
46
47
48
49
50
51
52

53
54
55 Based on the univariate and Cox multivariate analyses; advanced pathologic T stage,
56 pneumonectomy, and persistent N2 were independently associated with worse PFS. **The type of**
57
58
59

neoadjuvant treatment (CRT vs. chemotherapy) was not an independent prognostic factor associated with PFS (Table 3 and 4).

Discussion

The aim of this study was to evaluate treatment outcomes in a large sample of patients with stage IIIA-N2 NSCLC who received neoadjuvant CRT or chemotherapy followed by surgery. We also sought to determine predictors of survival. To our knowledge, this is the largest multicenter Spanish study to date to specifically evaluate treatment outcomes in this population of lung cancer patients—that is, patients diagnosed with stage IIIA-N2 NSCLC treated with CRT or chemotherapy followed by lobectomy or pneumonectomy.

Previous studies that have evaluated a similar treatment strategy (neoadjuvant therapy followed by surgery) have reported 5-year OS rates from 14% to 48%, with a median OS of 16-59 months [4, 5, 7-11]. In this context, the results of our series—5-year OS of 51.1% and median OS of 61 months—are promising. However, it should be emphasized that we included only patients who completed both neoadjuvant treatment and surgery. This is relevant because previous studies have shown lower survival rates in patients who do not undergo surgery as planned after neoadjuvant therapy [12, 13]. For example, Kim et al. [12] evaluated 664 patients with stage N1 NSCLC, 574 of whom completed the planned surgery. In that series, 5-year OS was worse in the patients who did not undergo surgery compared to the surgical patients (15% vs. 48%, $p < 0.0001$). Nonetheless, despite the selection bias in our study, we believe that our findings could potentially be extrapolated to other hospitals and regions due to the multicentric study design.

A substantial proportion (41.5%) of the patients in our sample did not undergo invasive mediastinal staging at any point. In Spain, the usual treatment for patients with N2 disease is neoadjuvant therapy followed by surgery. However, if the status of the mediastinal nodes is not confirmed histologically after neoadjuvant therapy, there is a risk of overdiagnosis as some

1 patients may be diagnosed incorrectly with persistent N2 disease [14] or underdiagnosis (e.g.,
2 occult N3 disease) [14], which could ultimately affect the treatment decision and patient
3 survival. That said, the presence or absence of histological confirmation was not a predictor of
4 survival in our study.
5
6
7

8
9
10 There is some controversy regarding the value of surgery in patients with multi-station N2
11 disease and/or bulky disease (≥ 3 cm) [15]. In our study, multiple nodal stations were involved in
12 39% of cases while 6.8% of patients had bulky disease; however, neither of these two factors
13 was associated with worse survival, a finding that suggests that surgery may be feasible in these
14 patients.
15
16
17
18
19

20
21
22 The optimal neoadjuvant scheme remains unclear [15]. This controversy is reflected in the
23 neoadjuvant treatment administered in our multicentric study, which was divided more or less
24 evenly between CRT (55.9%) and chemotherapy alone (44.1%). Interestingly, the specific
25 neoadjuvant therapy scheme, including high-dose induction CRT, was not predictive of survival
26 on the univariate analysis, perhaps because most of patients treated with chemotherapy alone
27 received postoperative radiotherapy. Although our study included patients treated with both low
28 (45-50 Gy) and high doses (60-66 Gy) of radiotherapy, a randomized trial is necessary to clarify
29 whether the efficacy of high dose (60 Gy at 2 Gy/session) CRT is comparable to chemotherapy
30 alone.
31
32
33
34
35
36
37
38
39
40
41

42
43 The value of performing invasive mediastinal staging after induction therapy prior to surgery is
44 also controversial [15]. Yang et al. evaluated 111 patients with stage IIIA pN2 NSCLC who
45 underwent induction therapy followed by lobectomy, finding that pathologic mediastinal
46 restaging allows clinicians to select those patients most likely to benefit from surgery; in that
47 study, mediastinal restaging vs. no restaging was associated with better 5-year OS (45.2% vs.
48 13.9%, $p=0.004$). Postoperative downstaging of the mediastinal nodes based on the surgical
49 specimen was associated with even better 5-year OS rates (59.2% vs. 28.5%, $p<0.001$) [16]. In
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

our study, pathologic mediastinal restaging following induction therapy was not a predictor of survival, perhaps due to the delayed response to neoadjuvant radiotherapy, which could explain why early mediastinal restaging after induction therapy may not correlate closely with the mediastinal downstaging observed in the surgical specimen.

We found no association between survival and the time interval from induction therapy to surgery. This finding contrasts with the results of a recent study [17] in which patients who underwent surgery >6 weeks after induction therapy had a worse OS, suggesting that 90-day postoperative mortality rates may increase due to radiation pneumonitis or fibrotic changes. Nonetheless, even though nearly 75% of patients in our sample underwent surgery more than 6 weeks after completing induction therapy, our 5-year OS rates are comparable to the best outcomes reported to date. Nonetheless, it should be noted that a large percentage of our sample (40%) received chemotherapy alone (rather than CRT), which could explain the reduced postoperative mortality associated with radiation pneumonitis.

With regards to the impact of the surgical procedure (pneumectomy vs. lobectomy) on treatment outcomes, we found no association between postoperative morbidity or mortality in patients who underwent pneumonectomy, probably due to careful patient selection (young age, good general and functional status). By contrast—consistent with the findings reported by Marulli et al. [18]—median OS was worse in the patients in our series who underwent pneumectomy compared to lobectomy (35 vs. 82 months). For this reason, as suggested by the findings of the Intergroup 0139 trial [4], the most appropriate treatment in these patients is probably dCRT.

Study strengths and limitations

The main limitation of the present study is its retrospective design, which could have led to a selection bias. In addition, we included only patients who underwent surgery after neoadjuvant therapy, and therefore the results cannot be generalized to all patients with stage IIIA-N2 NSCLC given that some patients never reach the surgical phase. Another potential limitation is

1 the heterogeneity of the sample, particularly the presence or lack of post-induction histological
2 confirmation of the mediastinal nodes and differences among the patients in the specific
3 neoadjuvant regime. However, a comprehensive regression analysis was performed to account
4 for differences in those two variables. Although the heterogeneity in our sample could be
5 considered a limitation, it is important to note that this variability in patient characteristics
6 reflects the complex and diverse nature of managing this patient population in routine clinical
7 practice.

16 **Conclusions**

19 In this retrospective, multi-institutional study involving patients with stage IIIA-N2 NSCLC,
20 neoadjuvant treatment followed by surgery achieved excellent long-term survival outcomes with
21 acceptable morbidity. Our findings suggest that the patients most likely to benefit from
22 multimodal treatment are: patients who undergo lobectomy (rather than pneumectomy), and
23 whose primary tumour and/or mediastinal lymph nodes are downstaged after induction therapy.
24 These findings provide further support for the use of neoadjuvant therapy followed by surgery
25 in selected patients.

36 **Acknowledgements**

39 The author wish to thank David Saldaña, Thoracic Surgery of Hospital Universitario Ramón y
40 Cajal, Madrid; Ignacio Muguruza Trueba, Thoracic Surgery of Hospital Universitario Rey Juan
41 Carlos, Móstoles; Pedro López Castro, Thoracic Surgery of Hospital Germans Trias i Pujol,
42 Badalona and Rafael Aguiló Espases, Thoracic Surgery of Hospital del Mar, Barcelona, for the
43 collaboration in this study. The author wish to thank Bradley Londres for translating and editing
44 this manuscript. The study was supported by the Radiation Oncology Clinical Research Group
45 (GICOR) and the GOECP-SEOR (Oncologic Group for the Study of Lung Cancer-Spanish
46 Society of Radiation Oncology).

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest

Research involving human participants and/or animals:

The present study involved human participants, and it was conducted considering ethical responsibilities according to the World Medical Association and the Declaration of Helsinki.

Informed consent

The study was approved by the ethics committees of all participating hospitals. Informed consent statement was not necessary for retrospective study. Patients provided informed consent for treatment as per standard procedure at the individual institutions.

Funding

The translation of this work was supported financially by the Spanish Society of Radiation Oncology.

Figure captions

Fig. 1 Overall survival according to: **a** nodal downstaging; **b** pathologic T stage; **c** type of surgery, and **d** presence of pathological complete response.

Fig. 2 Progression-free survival according to to: **a** nodal downstaging; **b** pathologic T stage; **c** type of surgery, and **d** presence of pathological complete response.

1 **References**

- 2
- 3 1. Martini et al. The role of surgery in N2 lung cancer. *Surg Clin North Am.* 1987;67:1037-
- 4 1049.
- 5
- 6 2. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, *et al.* Meta-analysis
- 7 of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung
- 8 cancer. *J Clin Oncol.* 2010;28(13):2181–90.
- 9
- 10
- 11
- 12
- 13
- 14 3. O’Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy
- 15 in non-small cell lung cancer. *Cochrane database Syst Rev.* 2010;(6):CD002140.
- 16
- 17
- 18
- 19
- 20 4. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, *et al.*
- 21 Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell
- 22 lung cancer: a phase III randomised controlled trial. *Lancet.* 2009;374(9687):379–86.
- 23
- 24
- 25
- 26
- 27
- 28 5. Pless M, Stupp R, Ris H, Stahel RA, Weder W, Thierstein S, *et al.* Final results of the SAKK
- 29 16/00 trial: A randomized phase III trial comparing neoadjuvant chemoradiation to
- 30 chemotherapy alone in stage IIIA/N2 non-small-cell lung cancer (NSCLC). *Ann Oncol.* Oxford
- 31 University Press; 2014;25(suppl 4):iv417-iv417.
- 32
- 33
- 34
- 35
- 36
- 37
- 38 6. Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, *et al.* A phase 3 study of
- 39 induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in
- 40 patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
- 41 *Cancer.* 2012;118(24):6126–35.
- 42
- 43
- 44
- 45
- 46
- 47
- 48 7. Eberhardt WEE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, *et al.* Phase III Study
- 49 of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable
- 50 Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy
- 51 and Concurrent Chemoradiotherapy (ESPATUE). *J Clin Oncol.* 2015;33(35):4194–201.
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
8. Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, *et al.* Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery. *Cancer Control*. 2014;21(1):57–62.
 9. Darling GE, Li F, Patsios D, Massey C, Wallis AG, Coate L, *et al.* Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer. *Eur J Cardio-Thoracic Surg*. 2015;48(5):684–90.
 10. Xu X-L, Dan L, Chen W, Zhu S-M, Mao W-M. Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) non small-cell lung cancer: a meta-analysis and system review. *Onco Targets Ther*. Dove Press. 2016; 9:845–53.
 11. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, *et al.* Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. *J Natl Cancer Inst*. 2007; 99 442-50.
 12. Kim HK, Cho JH, Choi YS, Zo JI, Shim YM, Park K, *et al.* Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. *Lung Cancer*. 2016; 96:56-62.
 13. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. *Ann Thorac Surg*. 2008; 86(3):912-20.
 14. Rocco G, Nason K, Brunelli A, Varela G, Waddell T, Jones DR. Management of stage IIIA (N2) non-small-cell lung cancer: a transatlantic perspective. *Eur J Cardiothorac Surg*. 2016;49 (4):1025-7.





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

15. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504-535.

16. Yang CF, Adil SM, Anderson KL, Meyerhoff RR, Turley RS, Hartwig MG, et al. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. Eur J Cardiothorac Surg. 2016;49(6):1607-13.

17. Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, et al. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):314-322.

18. Marulli G, Verderi E, Zuin A, Schiavon M, Battistella L, Perissinotto E, et al. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. Interact Cardiovasc Thorac Surg. 2014;19(2):256-62.









Table 1. Baseline characteristics of the study population

Variable	Surgery N=118 (%)
Age	
>60 y, n (%)	68 (57.6)
≤60 y, n (%)	50 (42.4)
Median (range)	62 (41-78)
Sex	
Male, n (%)	94 (79.7)
Female, n (%)	24 (20.3)
ECOG	
1-0	117 (99.2)
2	1 (0.8)
Smoking status	
Never, n(%)	4 (3.4)
Former, n(%)	55 (46.6)
Current, n (%)	59 (50.0)
T stage	
T1, n (%)	30 (25.6)
T2, n (%)	41 (35.0)
T3, n (%)	46 (39.3)
Number of positive nodal stations	
1, n (%)	
>1, n (%)	72 (61.0) 46 (39.0)
Mediastinal bulk	
<3 cm, n (%)	110 (93.2)
≥3 cm, n (%)	8 (6.8)
Histology	
Adenocarcinoma and others, n (%)	66 (57.4)
Squamous, n (%)	49 (42.6)

ECOG, eastern cooperative oncology group.

Table 4. Multivariate analysis for association of baseline characteristics and treatment-related variables with PFS and OS (n=118)

Variable	OS		PFS	
	HR (95% CI)	p	HR (95% CI)	p
Nodal downstaging (ypN2→ypN0-1) Yes (n=32) [ref: No (n=30)]	0.469 (0.261- 0.844)	0.011	0.282 (0.160 – 0.496)	<0.001
Pathologic stage pT ypT3 (n=13) [ref: ypT0-ypT2 (n=105)]	2.414 (1.163 – 5.011)	0.018	3.006 (1.472 – 6.141)	0.003
Surgery type Lobectomy (n=97) [ref: Pneumonectomy (n=21)]	0.453 (0.230 – 0.894)	0.022	0.502 (0.255 – 0.991)	0.047

Table 3. Univariate analysis for association of baseline characteristics and treatment-related variables with PFS and OS (n=118)

Variable	OS		PFS	
	HR (95% CI)	p	HR (95% CI)	p
Age, years				
≤60 (n=50) [ref: > 60 (n=68)]	0.687 (0.386- 1.223)	0.202	0.757 (0.437 - 1.309)	0.319
Sex				
women (n=24) [ref: men (n=94)]	0.449 (0.200 - 1.007)	0.052	0.853 (0.447 - 1.627)	0.629
ECOG				
2 (n=1) [ref: 0-1 (n=117)]	-	-	-	-
Smoking status				
Former (n=55) [ref: never (n=4)]	1.162 (0.275 – 4.904)	0.838	0.622 (0.189 – 2.046)	0.434
Current (n=59)	0.903 (0.211 - 3.861)	0.891	0.442 (0.132- 1.479)	0.185
T stage				
cT2 (n=41) [ref: cT1 (n=30)]	1.380 (0.657 – 2.899)	0.396	1.204 (0.600 – 2.415)	0.601
cT3 (n=46)	1.159 (0.549- 2.446)	0.699	1.143 (0.566 - 1.307)	0.709
Number of positive lymph nodal stations				
> 1 (n=46) [ref: 1 (n=72)]	1.295 (0.739 – 2.269)	0.366	1.320 (0.768 - 2.267)	0.315
Mediastinal lymph node size				
≥3 cm (n=8) [ref: < 3 cm (n=110)]	1.647 (0.651 – 4.166)	0.292	1.405 (0.506- 5.899)	0.513
Histology				
Squamous (n=49) [ref: Adenocarcinoma&others (n=66)]	1.191 (0.682 – 2.080)	0.538	0.913 (0.526 - 1.587)	0.748
Histopathological mediastinum confirmation before neoadjuvant treatment				
Yes (n=69) [ref: No (n=49)]	1.644 (0.904 - 2.989)	0.103	1.431 (0.809 - 2.531)	0.217
Neoadjuvant treatment				
CRT (n=66) [ref: CHT (n=52)]	0.856 (0.488 – 1.501)	0.587	0.744 (0.432 - 1.283)	0.288
Radiological re-evaluation prior to resection				
PET/CT (n=55) [ref: TC (n=63)]	0.770 (0.437-1.357)	0.366	0.679 (0.389-1.186)	0.174
Pathological mediastinal re-evaluation prior to resection				
Yes (n=47) [ref: No (n=71)]	0.956 (0.542-1.688)	0.877	0.775 (0.440-1.367)	0.379
Interval to surgery after completion of induction treatment				
>3 to ≤6 weeks, (n=28) [ref:0-3 wk (n=3)]	0.299 (0.064-1.388)	0.123	0.428 (0.095-1.920)	0.268
>6 to ≤9 weeks, (n=40)	0.299 (0.067-1.333)	0.113	0.323 (0.073-1.440)	0.138
>9 to ≤12 weeks, (n=17)	0.601 (0.130-2.769)	0.513	0.660 (0.144-3.023)	0.592
>12 weeks, (n=29)	0.400 (0.090-1.784)	0.230	0.476 (0.107-2.109)	0.328
Pathologic stage pT				
pT3 (n=13) [ref: ypT0-pT2 (n=105)]	3.141 (1.561-6323)	0.001	3.846 (1.954-7.568)	<0.001

Continue Table 3. Univariate analysis for association of baseline characteristics and treatment-related variables

Variable	OS		PFS	
	HR (95% CI)	p	HR (95% CI)	p
Nodal downstaging (N2→N0-1)				
Yes (n=88) [ref: No (n=30)]	0.442 (0.250- 0.781)	0.005	0.284 (0.164- 0.491)	<0.001
Margin status				
R1/R2 (n=4) [ref: R0 (n=113)]	1.100 (0.151 – 8.022)	0.925	2.143 (0.520 - 8.833)	0.292
Surgery type				
Lobectomy (n=97) [ref: Pneumonectomy (n=21)]	0.441 (0.229 – 0.851)	0.015	0.513 (0.269 – 0.979)	0.043
Pathologic complete response (pT0pN0)				
Yes (n=32) [ref: No (n=86)]	0.569 (0.276 – 1.174)	0.127	0.495 (0.241 – 1.016)	0.055
Adjuvant treatment				
RT (n=20) [ref: CHT (n=20)]	1.565 (0.618-3.967)	0.345	1.649 (0.709-3.839)	0.246
CRT (n=11)	0.800 (0.278-2.302)	0.678	0.723 (0.255-2.051)	0.542

Table 4. Multivariate analysis for association of baseline characteristics and treatment-related variables with PFS and OS (n=118)

Variable	OS		PFS	
	HR (95% CI)	p	HR (95% CI)	p
Nodal downstaging (pN2→pN0-1) Yes (n=32) [ref: No (n=30)]	0.469 (0.261- 0.844)	0.011	0.282 (0.160 – 0.496)	<0.001
Pathologic stage pT ypT3 (n=13) [ref: ypT0-ypT2 (n=105)]	2.414 (1.163 – 5.011)	0.018	3.006 (1.472 – 6.141)	0.003
Surgery type Lobectomy (n=97) [ref: Pneumonectomy (n=21)]	0.453 (0.230 – 0.894)	0.022	0.502 (0.255 – 0.991)	0.047